Why Medical Device Market Access Decisions Set Your Real Launch Date Before FDA Clearance Lands

Key Takeaways

• Medical device market access is a pre-clearance discipline, not a post-launch problem to solve once you have a cleared device
• Stanford research puts the average time from clearance to meaningful reimbursement at 5.7 years, and most founders had no plan for those years going in
• The CPT code structure (Category I vs Category III) determines whether reimbursement is secure or just a tracking code with no payer obligation
• IDE study design choices made before the pivotal trial can produce secondary endpoints that later become HEOR materials at no additional cost
• VAC navigation runs on relationship cartography (every named stakeholder, their stance, their movement) and not on product features

You closed your Series B. The pivotal trial is enrolling. The board's commercial timeline has the company launching twelve months after expected FDA clearance, hitting first revenue in quarter two post-launch, and scaling reps in quarter four.

The medical device market access work is on the deck somewhere, scheduled to start after clearance.

But your real launch date isn't when the FDA clears the device. It's when the first payer covers the procedure code, the first Value Analysis Committee approves the purchase, and the first IDN signs the contract that lets your reps call on accounts in that network.

So the gap between clearance and that first paid revenue is what the company has to fund, and the gap is usually a multiple of what the original plan assumed.

This post lays out why medical device market access has to be engineered two years before clearance, what the specific pre-clearance moves are, and the data points medtech founders need on the board call about commercial timeline.

The 5.7-Year Reality Behind "Meaningful Reimbursement"

The first data point most founders miss is the time from FDA clearance to meaningful reimbursement. The number is much longer than the average commercial deck assumes.

A Stanford study published in JAMA Health Forum put the average time from FDA clearance to meaningful reimbursement at 5.7 years.

Some categories run faster, some run longer. But the operating implication is that if your company has 24 months of runway post-launch and no medical device market access work done pre-clearance, the math doesn't close. The reimbursement won't be in place before the runway runs out.

The companies that beat that average usually started medical device market access work 18 to 24 months before clearance. The companies that hit the 5.7 year average mostly started the work after clearance, when payers were already evaluating the technology category and the founder was negotiating from a weaker position.

How CPT Code Structure Decides Whether Reimbursement Is Secure or Tracked

The cleanest gate inside medical device market access is the CPT code structure. The category of code your procedure ends up under determines whether reimbursement is secure or just tracked.

I interviewed Josh Makower on an episode about whether the FDA and AMA are killing medtech innovation. Josh walked through the code structure directly:

"You need a what's called a category one code to really secure reimbursement. There's another type of code let's call that is called a category three that is generally referred to as a tracking code. That doesn't mean you that is not a guarantee of any kind of reimbursement."

So Category I is the secure code. Category III is the tracking code. Most newer medical device technologies land first in Category III, which lets payers track utilization but doesn't obligate them to pay. Moving from Category III to Category I requires five years of utilization data, peer-reviewed publications, and an AMA panel review.

Founders who don't know which code category their procedure will land in have not started medical device market access work. The CPT code path is the first artifact every medical device market access plan should produce, and it should be in the founder's hands before the pivotal trial starts enrolling.

Engineering Secondary Endpoints That Become HEOR Materials

The most expensive piece of medical device market access work to skip is the one that costs almost nothing if you sequence it correctly. Pivotal trial design can include secondary endpoints that later become Health Economics and Outcomes Research materials, but only if the design choice is made before the trial starts.

I covered this on an episode about how a billion-dollar M&A machine drives medtech growth:

"demonstrable clinical value. And the piece I would say is oftentimes if you plan early enough, you can get secondary or observational data points out of your IDE study for free that can then be baked into your HR materials."

So the work is free if planned early. It's a million-dollar standalone study if not. The pre-clearance medical device market access plan should include a list of HEOR data points the IDE study could capture as secondary endpoints. The list should be reviewed with payer-side advisors who know what specific data points each major payer requires for coverage decisions.

That review should happen 12 to 18 months before the pivotal trial protocol is finalised. The trial protocol is hard to change after it's locked. So the review window is narrow, and most founders miss it because the medical device market access work hasn't started yet.

Pricing as a Market Maturity Signal

The next pre-clearance lever inside medical device market access is pricing. Most founders treat pricing as a post-launch revenue question. Pricing is also a signal to payers, hospitals, and investors about what category the product belongs in.

On the $100B exit fix episode about mini strategics, I named the pricing-as-signal dynamic:

"engineer your pricing and reimbursement economics early. This sounds like it's common sense, but a lot of people don't do this. Pricing isn't really just about revenue. It's essentially how you signal market maturity and acquire reimbursement leverage."

Underpricing signals immaturity. Overpricing without clinical evidence signals lack of payer discipline. Pricing aligned to a defensible cost-effectiveness story that lines up with the HEOR data the pivotal trial will produce signals to payers that the company knows what category it's competing in. So the pricing decision should be made alongside the trial design decision, not after launch.

How VAC Navigation Runs on Relationship Cartography Before Product Features

The final piece of medical device market access work that has to happen pre-launch is Value Analysis Committee mapping. Once the device is cleared and the reps are calling on hospitals, the VAC process becomes the gate. The companies that move through VAC fastest started mapping the stakeholders months before the first rep walked in.

I interviewed Mark Copeland on an episode about secrets to selling to the hospital Value Analysis Committee. Mark walked through the relationship cartography he uses on every account:

"I chart it I put down the left-hand side here's all the important people and across the top I say are they against us do they not care do they love it and I try to move everybody one to the right"

That chart is the operational unit of medical device market access at the hospital level. Every named stakeholder, every stance, every movement over time. The companies that win VACs run this cartography on every priority account before the rep ever walks in.

They know which materials each stakeholder needs, who needs to be moved first, and what specific objections the surgeon champion will face from the procurement lead.

The chart can't be built post-clearance. It has to be built pre-launch, with input from the design partners, KOLs, and clinical-trial sites that already have line of sight into the buying committees.

What This Means for Medtech Founders

In my experience working with medtech founders, the medical device market access conversation usually starts six months too late. It starts after clearance, when reps are already in the field and the company is trying to understand why deals aren't closing as fast as the plan predicted.

So the better practice is to put a medical device market access lead on the team before the pivotal trial starts enrolling. The lead's job is to design the CPT code path, the HEOR data capture plan, the pricing-as-signal logic, and the VAC stakeholder maps that the commercial team will need to execute post-launch.

None of those four deliverables can be built fast post-clearance. All four are cheap to build pre-clearance if they're sequenced into the existing pivotal trial and commercial-build work.

For more on the commercial sequencing that has to happen alongside medical device market access work, read the medtech commercialisation strategy framework and the medtech go-to-market strategy playbook.

Frequently Asked Questions

What is medical device market access?

Medical device market access is the set of disciplines that determines whether a cleared device can be purchased, reimbursed, and used at scale.

The work spans CPT and HCPCS code strategy, payer coverage and coding decisions, Health Economics and Outcomes Research data design, IDN and GPO contracting, hospital Value Analysis Committee navigation, and pricing strategy. Strong medical device market access work starts 18 to 24 months before FDA clearance.

How long does it take to get medical device market access after FDA clearance?

Stanford research puts the average time from FDA clearance to meaningful reimbursement at 5.7 years. The number varies by therapeutic area, CPT code structure, payer mix, and category novelty. Companies that started medical device market access work pre-clearance can compress this window meaningfully. Companies that defer the work until post-clearance typically hit the 5.7 year average or longer.

What is the difference between Category I and Category III CPT codes for medical devices?

Category I CPT codes provide secure reimbursement, with payer payment obligations attached. Category III CPT codes are tracking codes that allow payers to monitor utilization but carry no payment obligation. Most novel medical device technologies start in Category III.

Moving from Category III to Category I requires three to five years of utilization data, peer-reviewed publications, and AMA panel review. Founders should know which code category their procedure will fall into before the pivotal trial enrolls.

How should medtech founders prepare for hospital Value Analysis Committees?

VAC preparation should start before the first sales rep walks into the hospital. The work involves stakeholder cartography (mapping every named decision-maker on every priority account), stance tracking (against, neutral, supportive), and movement planning (what each stakeholder needs to move one column to the right).

The cartography is built with input from design partners, KOLs, and clinical-trial sites that already have line of sight into the buying committee at each target hospital.

Listen to the Full Conversations

The episodes referenced in this post are available on The State of MedTech. Subscribe wherever you listen to podcasts.

• Is the FDA & AMA Killing Medtech Innovation? Josh Makower
• How DermaSensor is Scaling Clinical Adoption Using B2C Strategies
• Secrets to Selling to the Hospital Value Analysis Committee with Mark Copeland
• How a Billion-Dollar M&A Machine Drives MedTech Growth
• $100B Exit Fix: How Mini Strategics Are Winning

About the Author

Omar Khateeb is the founder of MarketCraft and host of The State of MedTech, the number one podcast in the medtech industry. He works with medtech founders and commercial leaders on market engineering, commercialisation strategy, and revenue growth. Visit marketcraft.ai or subscribe to The State of MedTech for weekly conversations with the people building the future of medical devices.